The World Health Organization's ATC classification organizes medical drugs based on therapeutic properties, chemical composition, and anatomy. It helps make essential medicines readily available globally and is widely used in the pharmaceutical industry.
Level | Code | Title | |
---|---|---|---|
1 | R | Respiratory system | |
2 | R07 | Other respiratory system products | |
3 | R07A | Other respiratory system products |
Code | Title | |
---|---|---|
R07AA | Lung surfactants | |
R07AB | Respiratory stimulants | |
R07AX | Other respiratory system products |
Active Ingredient | Description | |
---|---|---|
Almitrine |
Almitrine is a diphenylmethylpiperazine derivative and respiratory stimulant that enhances respiration by acting as an agonist of peripheral chemoreceptors located on the carotid bodies. It is used in the treatment of chronic obstructive pulmonary disease. It is also reported to have a potentially beneficial effect in treating the noctural oxygen desaturation without impairing the quality of sleep. |
|
Bacterial lysates |
Bacterial lysates are powerful inducers of a specific locoregional immune response that significantly enhance the concentration of antibodies directed to antigenic structures of bacteria most commonly observed during infections of the upper respiratory tract. |
|
Bemegride |
Bemegride is a CNS stimulant that is used to induce convulsions in experimental animals. It has also been used as a respiratory stimulant and in the treatment of barbiturate overdose. Bemegride is an antidote for barbiturate poisoning. Bemegride has being shown to have an antagonistic action on the GABAA receptor. |
|
Beractant |
|
|
Doxapram |
Doxapram is an analeptic agent (a stimulant of the central nervous system). Doxapram produces respiratory stimulation mediated through the peripheral carotid chemoreceptors. It is thought to stimulate the carotid body by inhibiting certain potassium channels. Used as temporary measure in hospitalized patients with acute respiratory insufficiency superimposed on chronic obstructive pulmonary disease. |
|
Ivacaftor |
Ivacaftor is a potentiator of the CFTR protein, i.e., in vitro ivacaftor increases CFTR channel gating to enhance chloride transport in specified gating mutations with reduced channel-open probability compared to normal CFTR. Ivacaftor also potentiated the channel-open probability of R117H-CFTR, which has both low channel-open probability (gating) and reduced channel current amplitude (conductance). |
|
Ivacaftor and Lumacaftor |
The combined effect of lumacaftor and ivacaftor is increased quantity and function of F508del |
|
Ivacaftor, Tezacaftor and Elexacaftor |
Elexacaftor and tezacaftor are CFTR correctors that bind to different sites on the CFTR protein and have an additive effect in facilitating the cellular processing and trafficking of F508del-CFTR to increase the amount of CFTR protein delivered to the cell surface compared to either molecule alone. Ivacaftor potentiates the channel open probability (or gating) of the CFTR protein at the cell surface. The combined effect of elexacaftor, tezacaftor and ivacaftor is increased quantity and function of F508del-CFTR at the cell surface, resulting in increased CFTR activity as measured by CFTR mediated chloride transport. |
|
Lumacaftor |
|
|
Nikethamide |
|
|
Nitric oxide (NO) |
Nitric oxide is a compound produced by many cells of the body. It relaxes vascular smooth muscle by binding to the haeme moiety of cytosolic guanylate cyclase. When inhaled, nitric oxide produces selective pulmonary vasodilation. |
|
Natural phospholipids |
|
Title | Information Source | Document Type | |
---|---|---|---|
DOPRAM Solution for injection | FDA, National Drug Code (US) | MPI, US: SPL/Old | |
DOPRAM Sterile solution for injection | Medicines & Healthcare Products Regulatory Agency (GB) | MPI, EU: SmPC | |
Doxapram Hydrochloride 2mg/ml Solution for Infusion | Medicines & Healthcare Products Regulatory Agency (GB) | MPI, EU: SmPC | |
INFASURF Suspension | FDA, National Drug Code (US) | MPI, US: SPL/Old | |
INOMAX Inhalation gas | European Medicines Agency (EU) | MPI, EU: SmPC | |
KAFTRIO Film-coated tablet | European Medicines Agency (EU) | MPI, EU: SmPC | |
KAFTRIO Granules | European Medicines Agency (EU) | MPI, EU: SmPC | |
KALYDECO Film-coated tablet | European Medicines Agency (EU) | MPI, EU: SmPC | |
KALYDECO Granules | European Medicines Agency (EU) | MPI, EU: SmPC | |
KINOX Inhalation gas | Health Products and Food Branch (CA) | MPI, CA: SPM | |
NEOPHYR Medicinal gas, compressed | Health Products Regulatory Authority (IE) | MPI, EU: SmPC | |
NOXIVENT 101 Inhalation gas | FDA, National Drug Code (US) | MPI, US: SPL/PLR | |
ORKAMBI Film-coated tablet | European Medicines Agency (EU) | MPI, EU: SmPC | |
ORKAMBI Granules | European Medicines Agency (EU) | MPI, EU: SmPC |